CLEARMIND MEDICINE INC (CMND)

CA1850534027 - Common Stock

1.2  +0.01 (+0.84%)

Fundamental Rating

1

CMND gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. CMND may be in some trouble as it scores bad on both profitability and health. CMND does not seem to be growing, but still is valued expensively.



0

1. Profitability

1.1 Basic Checks

CMND had negative earnings in the past year.
CMND had a negative operating cash flow in the past year.
CMND had negative earnings in each of the past 5 years.
CMND had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of CMND (-103.26%) is worse than 76.44% of its industry peers.
CMND has a worse Return On Equity (-243.02%) than 73.82% of its industry peers.
Industry RankSector Rank
ROA -103.26%
ROE -243.02%
ROIC N/A
ROA(3y)-350.4%
ROA(5y)-231.15%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CMND so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, CMND has more shares outstanding
Compared to 5 years ago, CMND has more shares outstanding
CMND has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -4.70, we must say that CMND is in the distress zone and has some risk of bankruptcy.
CMND has a Altman-Z score of -4.70. This is in the lower half of the industry: CMND underperforms 63.35% of its industry peers.
CMND has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
CMND's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. CMND outperforms 58.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -4.7
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

CMND has a Current Ratio of 1.71. This is a normal value and indicates that CMND is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.71, CMND is doing worse than 63.87% of the companies in the same industry.
CMND has a Quick Ratio of 1.71. This is a normal value and indicates that CMND is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of CMND (1.71) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.71
Quick Ratio 1.71

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 65.74% over the past year.
EPS 1Y (TTM)65.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CMND. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for CMND!.
Industry RankSector Rank
Dividend Yield N/A

CLEARMIND MEDICINE INC

NASDAQ:CMND (12/20/2024, 8:02:54 PM)

1.2

+0.01 (+0.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners7.17%
Inst Owner Change317.4%
Ins Owners5.63%
Ins Owner Change0%
Market Cap5.26M
AnalystsN/A
Price TargetN/A
Short Float %4.72%
Short Ratio0.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.51
P/tB 1.56
EV/EBITDA N/A
EPS(TTM)-12.73
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1.04
OCFYN/A
SpS0
BVpS0.79
TBVpS0.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -103.26%
ROE -243.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-350.4%
ROA(5y)-231.15%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.71
Quick Ratio 1.71
Altman-Z -4.7
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)432.15%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.84%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y31.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.08%
OCF growth 3YN/A
OCF growth 5YN/A